Alterity Therapeutics Limited Stock Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 4.540 USD | +0.44% |
|
+0.67% | +47.40% |
| Market Cap | 78.75M 67.76M 63.76M 58.24M 109M 7.44B 109M 753M 292M 3.81B 296M 289M 12.29B | P/E 2027 * |
-0.39x | P/E 2028 * | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 37.85M 32.57M 30.64M 27.99M 52.36M 3.57B 52.51M 362M 141M 1.83B 142M 139M 5.91B | EV / Sales 2027 * |
66.3x | EV / Sales 2028 * | 18x |
| Free-Float |
92.97% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ATHE | Delayed | |
CBOE
| ATHE | Real-time | |
|
Deutsche Boerse AG
| PBN0 | Delayed | |
|
Börse Stuttgart
| PBN0 | Delayed |
Last Transcript : Alterity Therapeutics Limited
| 1 day | +0.44% | ||
| 1 week | +0.67% | ||
| Current month | +1.11% | ||
| 1 month | +3.32% | ||
| 3 months | +16.41% | ||
| 6 months | +33.53% | ||
| Current year | +47.40% |
| 1 week | 4.4 |  | 4.72 |
| 1 month | 4.31 | | 5.04 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 5.89 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 13.9 |
| 10 years | 1 | | 53.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 2021-01-06 |
| Director of Finance/CFO | - | 2024-09-29 | |
| Chief Tech/Sci/R&D Officer | - | 2019-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 2005-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 2011-08-07 |
David Stamler
BRD | Director/Board Member | 65 | 2025-11-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.44% | +0.67% | - | - | 79.4M | |
| -2.54% | -2.84% | -1.90% | +14.52% | 50.35B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.2B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.71B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 41.24B | |
| +0.53% | -1.36% | +16.04% | +48.23% | 33.08B | |
| -0.21% | +9.14% | - | - | 17.81B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.56B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.82B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 14B | |
| Average | -0.78% | +0.49% | +78.42% | +104.33% | 30.86B | |
| Weighted average by Cap. | -1.04% | +0.26% | +94.35% | +121.44% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 571K 491K 462K 422K 789K 53.87M 791K 5.46M 2.12M 27.64M 2.14M 2.1M 89.03M | 2.31M 1.99M 1.87M 1.71M 3.19M 218M 3.2M 22.08M 8.57M 112M 8.67M 8.48M 360M |
| Net income | -26.81M -23.07M -21.7M -19.83M -37.09M -2.53B -37.19M -256M -99.52M -1.3B -101M -98.47M -4.18B | -29.79M -25.64M -24.12M -22.03M -41.22M -2.81B -41.33M -285M -111M -1.44B -112M -109M -4.65B |
| Net Debt | -40.9M -35.2M -33.11M -30.25M -56.59M -3.86B -56.74M -391M -152M -1.98B -154M -150M -6.38B | -37.15M -31.97M -30.08M -27.48M -51.4M -3.51B -51.54M -355M -138M -1.8B -140M -136M -5.8B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | US$4.540 | +0.44% | 4,562 |
| 26-09-03 | US$4.520 | 0.00% | 13,255 |
| 26-09-02 | US$4.520 | -0.66% | 7,364 |
| 26-09-01 | US$4.550 | +1.34% | 13,202 |
| 26-08-31 | US$4.490 | -0.44% | 8,708 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
